Abstract withdrawn
- PDF / 80,771 Bytes
- 1 Pages / 595.28 x 793.7 pts Page_size
- 70 Downloads / 227 Views
ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY
MEETING ABSTRACT
Open Access
Asthma control using a combination of mometasone furoate/formoterol: grouped analysis of three clinical trials Martha White1*, Hendrik Nolte2, Eli Meltzer3, Robert Nathan4 From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2011 Quebec, Canada. 20-23 October 2011 Objective We characterized the ability of mometasone furoate/ formoterol (MF/F) combination to improve asthma control in adults/adolescents inadequately controlled on low-, medium-, and high-dose inhaled corticosteroids (ICS). Methods Changes from baseline to endpoint (last evaluable visit) in Asthma Control Questionnaire (ACQ) scores were assessed in subjects from 3 Phase III trials (low- [n=746], medium- [n=781], and high-dose [n=728] previous ICS use). The ACQ categorizes asthma symptoms and use of rescue-medication using a 7-point scale (0=totally controlled, 6=severely uncontrolled). In two placebo controlled trials, subjects were randomized to receive MF/F (100/10μg or 200/10μg), MF (100μg or 200μg), F (10μg), or placebo (26 weeks; all twice-daily [BID] via metereddose inhaler [MDI]); In a non-placebo controlled trial, subjects were randomized to receive MF/F 200/10μg, MF/F 400/10μg, or MF 400μg (12 weeks; all BID via MDI). Results Baseline ACQ scores (1.23–1.38 (MF/F 100/10μg study), 1.41–1.47 (MF/F 200/10μg study), and 1.83–1.87 (MF/F 200/10 and 400/10μg study) indicated that subjects in all trials were not well controlled (
Data Loading...
